TIMP-1 Overexpression Promotes Tumorigenesis of MDA-MB-231 Breast Cancer Cells and Alters Expression of a Subset of Cancer Promoting Genes in Vivo Distinct from Those Observed in Vitro
Overview
Affiliations
TIMP-1 (Tissue inhibitor of matrix metalloproteinase-1) is typically associated with inhibition of matrix metalloproteinases (MMP) induced invasion. However, TIMP-1 is overexpressed in many malignancies and is associated with poor prognosis in breast cancer. The mechanisms by which TIMP-1 promotes tumorigenesis are unclear. Reduced levels of TIMP-1 mediated by shRNA in MDA-MB-231 breast cancer cells had no effect on cellular physiology in vitro or tumor growth in SCID mice compared to vector control MDA-MB-231 cells. However, overexpression of TIMP-1 in MDA-MB-231 cells resulted in inhibition of cell invasion and enhanced phosphorylation of p38 MAPK and AKT in vitro. Additionally, treatment of parental MDA-MB-231 cells with purified TIMP-1 protein led to activation of p38 MAPK and MKK 3/6. cDNA array analysis demonstrated that high expression of TIMP-1 in MDA-MB-231 cells resulted in alterations in expression of approximately 200 genes, 1.5 fold or greater compared to vector control cells (P < 0.1). Real-time RT-PCR confirmed changes in expression of several genes associated with cancer progression including DAPK1, FGFR4 and MAPK13. In vivo, high TIMP-1 expression induced tumor growth in SCID mice compared to vector control cells and increased tumor vessel density. Affymetrix array analysis of vector control and TIMP-1 MDA-MB-231 xenograft tumors revealed that TIMP-1 altered expression of approximately 600 genes in vivo, including MMP1, MMP13, S100A14, S100P, Rab25 and ID4. These combined observations suggest that the effects of TIMP-1 differ significantly in a 2-D environment compared to the 3-D environment and that TIMP-1 stimulates tumor growth.
The TIMP protein family: diverse roles in pathophysiology.
Coates-Park S, Rich J, Stetler-Stevenson W, Peeney D Am J Physiol Cell Physiol. 2024; 326(3):C917-C934.
PMID: 38284123 PMC: 11193487. DOI: 10.1152/ajpcell.00699.2023.
Wang Y, He J, Tsai C, Tzeng H, Chang W, Pan S Life (Basel). 2024; 14(1).
PMID: 38276258 PMC: 10817502. DOI: 10.3390/life14010009.
A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer.
Grosgeorges M, Picque Lasorsa L, Pastor B, Prevostel C, Crapez E, Sanchez C Sci Rep. 2023; 13(1):2739.
PMID: 36792801 PMC: 9932139. DOI: 10.1038/s41598-023-29948-4.
Matrix metalloproteinases as therapeutic targets in breast cancer.
Kwon M Front Oncol. 2023; 12:1108695.
PMID: 36741729 PMC: 9897057. DOI: 10.3389/fonc.2022.1108695.
RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review.
Faruqui T, Khan M, Akhter Y, Khan S, Rafi Z, Saeed M Int J Mol Sci. 2023; 24(1).
PMID: 36613714 PMC: 9820344. DOI: 10.3390/ijms24010266.